Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?

Author： Mosna Federico   Capelli Debora   Gottardi Michele  

Publisher： MDPI

E-ISSN： 2077-0383|6|6|57-57

ISSN： 2077-0383

Source： Journal of Clinical Medicine, Vol.6, Iss.6, 2017-06, pp. : 57-57

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia

By Lamble Adam   Phelan Rachel   Burke Michael  

Journal of Clinical Medicine, Vol. 6, Iss. 7, 2017-07 ,pp. : 66-66

MDPI

Access to resources Recommend Favorite

Dasatinib: In Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

By Keam Susan J.  

BioDrugs, Vol. 22, Iss. 1, 2008-01 ,pp. : 59-69

Adis International

Access to resources Recommend Favorite

Use of Interleukin-2 in the Management of Haematological Malignancies: Focus on Minimal Residual Disease

By Mandelli F.   Capria S.   Vignetti M.   Meloni G.  

BioDrugs, Vol. 12, Iss. 1, 1999-07 ,pp. : 43-53

Adis International

Access to resources Recommend Favorite

Spotlight on Dasatinib in Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia†

By McCormack Paul L.   Keam Susan J.  

BioDrugs, Vol. 26, Iss. 1, 2012-02 ,pp. : 61-64

Adis International

Access to resources Recommend Favorite

A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia

By  

Clinical Case Reports, Vol. 3, Iss. 6, 2015-06 ,pp. : 448-452

John Wiley & Sons Inc

Access to resources Recommend Favorite